IL6 and type 2 diabetes mellitus: Our research suggests that while canakinumab significantly reduces markers of subclinical inflammation like hsCRP and IL-6 (which do predict development of T2DM) and incidence of MACE in patients with overt diabetes, pre-diabetes and normoglycemia; it does not reduce rates of incident T2DM or cause a significant sustained reduction in HbA1C levels in those with T2DM or IGT.